+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Diagnostics Market Report and Forecast 2024-2032

  • PDF Icon


  • 140 Pages
  • May 2024
  • Region: Global
  • Expert Market Research
  • ID: 5973981

The global cancer diagnostics market size was valued at USD 106.24 billion in 2023. It is expected to grow at a CAGR of 9.12% during the forecast period of 2024-2032, driven by the government initiatives and funding for cancer research across the globe. The market is experiencing robust growth and is expected to reach USD 231.93 billion by 2032.

Global Cancer Diagnostics Market Analysis

The global cancer diagnostics market is experiencing significant growth, driven by the rising incidence of cancer worldwide, advancements in diagnostic technologies, and an increasing emphasis on early detection to improve treatment outcomes. This analysis provides an overview of the current state of the market, key drivers, challenges, and emerging trends, offering insights into the future trajectory of cancer diagnostics.

Global Cancer Diagnostics Market Drivers

Several factors are propelling the growth of the cancer diagnostics market. Firstly, the global increase in cancer prevalence necessitates robust diagnostic solutions for early detection and management. Secondly, technological advancements in diagnostics, such as next-generation sequencing (NGS), are enhancing the accuracy and efficiency of cancer detection. Furthermore, government initiatives and funding for cancer research are supporting the development and adoption of advanced diagnostic methods. Lastly, the growing preference for personalized medicine is driving demand for precise diagnostic tools that can guide tailored treatment approaches.

Market Challenges

Despite the growth, the market faces challenges, including the high cost of advanced diagnostic tests, which may limit accessibility in low- and middle-income countries. Additionally, the complexity of regulatory approvals for new diagnostic technologies can delay their market entry and adoption. There's also a critical need for skilled professionals to operate advanced diagnostic equipment and interpret results accurately, posing a barrier to the widespread implementation of new technologies.

Global Cancer Diagnostics Market Outlook

The global cancer diagnostics market is poised for continued growth, with an increasing emphasis on early detection, minimally invasive diagnostic methods, and integration of digital technologies to improve diagnostic accuracy and patient outcomes. As research progresses and awareness increases, the market is expected to witness the introduction of more innovative diagnostic solutions, catering to the evolving needs of healthcare providers and patients alike. Collaboration among research institutions, industry players, and regulatory bodies will be key to overcoming existing challenges and fully realizing the potential of advanced cancer diagnostics in improving global health outcomes.

Global Cancer Diagnostics Market Trends

The global cancer diagnostics market is witnessing significant growth, driven by technological advancements, increasing prevalence of cancer worldwide, and a growing emphasis on early detection and personalized treatment. The following trends are shaping the future of cancer diagnostics:

1. Technological Innovations

Rapid advancements in diagnostic technologies, including next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI)-enhanced imaging, are transforming cancer diagnostics. These innovations enable more precise, non-invasive, and early detection of cancer, facilitating personalized treatment plans and improving patient outcomes.

2. Liquid Biopsy Emergence

Liquid biopsy is gaining traction as a revolutionary approach for cancer detection and monitoring. This minimally invasive technique analyzes circulating tumor DNA (ctDNA) in blood samples to detect cancer at early stages, monitor treatment response, and identify molecular changes without the need for traditional biopsy procedures. Its convenience and efficiency are driving its adoption in clinical settings.

3. Increased Focus on Personalized Medicine

The shift towards personalized or precision medicine is profoundly impacting the cancer diagnostics market. Personalized treatment plans based on genetics, biomarker, and other molecular data are becoming the norm, necessitating advanced diagnostics to identify specific cancer types and their genetic mutations. This approach ensures more targeted and effective treatments, driving demand for sophisticated diagnostic tests.

4. Rising Cancer Prevalence

The global increase in cancer cases is a primary driver for the expansion of the cancer diagnostics market. Aging populations, lifestyle factors, and environmental influences contribute to rising cancer rates, highlighting the need for advanced diagnostic solutions to manage the growing burden of this disease.

5. Integration of Artificial Intelligence

AI is playing a crucial role in enhancing the accuracy, speed, and efficiency of cancer diagnostics. AI algorithms are being used to interpret complex imaging data, identify patterns not visible to the human eye, and predict disease progression. This integration improves diagnostic precision and facilitating faster decision-making in treatment planning.

6. Expanding Applications of Genomic Testing

Genomic testing is at the forefront of identifying genetic predispositions to various cancers, understanding tumor genetics, and selecting targeted therapies. The declining cost of genomic sequencing and the growing understanding of genetic markers in cancer are expanding the use of genomic testing in oncology.

7. Regulatory and Reimbursement Landscape Evolution

The regulatory and reimbursement environment is evolving to keep pace with rapid technological advancements in cancer diagnostics. Governments and insurance providers are increasingly recognizing the value of early and accurate cancer detection, leading to more supportive policies and reimbursement frameworks for innovative diagnostic tests.

8. Collaboration and Mergers

Strategic collaborations and mergers between diagnostic companies, pharmaceutical firms, and technology providers are becoming common. These partnerships aim to combine expertise in different areas, such as biomarker discovery, diagnostic technology development, and AI, to accelerate the development and commercialization of advanced cancer diagnostic solutions.

9. Emerging Markets Growth

The cancer diagnostics market is expanding rapidly in emerging economies, driven by increasing healthcare spending, growing awareness of early cancer detection, and improvements in healthcare infrastructure. This expansion presents significant opportunities for market growth and innovation.

10. Patient Empowerment and Awareness

There is a growing emphasis on patient empowerment and awareness regarding the importance of early cancer detection. Educational initiatives and screening programs are increasing public knowledge about cancer symptoms and the availability of diagnostic tests, encouraging people to seek early diagnosis and treatment.

Global Cancer Diagnostics Market Segmentation

Market Breakup by Product Type

  • Consumables
  • Instruments

The global cancer diagnostics market is segmented into consumables and instruments, both of which are pivotal for the market's expansion. Consumables, due to their recurrent usage and the growing need for precision diagnostics, are driving consistent demand, supporting ongoing market growth. Instruments, on the other hand, with technological advancements and integration of AI and genomic testing, are set to revolutionize cancer detection and treatment, indicating substantial future growth. Together, these segments underpin the market's trajectory, poised to significantly contribute to its expansion in the forecast period through innovation and increasing diagnostic accuracy.

Market Breakup by Technology

  • In-Vitro Diagnostics
  • Imaging
  • Biopsy Instruments
  • Others

The global cancer diagnostics market, segmented by technology into in-vitro diagnostics, imaging, biopsy instruments, and others, showcases diverse growth drivers. In-vitro diagnostics, with advancements in genomic testing, plays a crucial role in personalized medicine, indicating strong future growth. Imaging technologies, enhanced by AI, are revolutionizing early and precise cancer detection, promising significant market expansion. Biopsy Instruments, though traditional, remain indispensable for definitive diagnoses, evolving with less invasive techniques. The "Others" category, encompassing emerging technologies, hints at untapped potential driving innovation. Collectively, these segments are foundational to the market's growth, each contributing uniquely to the broadening scope and precision of cancer diagnostics in the forecast period.

Market Breakup by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Others

The global cancer diagnostics market, when analyzed by application, spans several key areas: lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and others. Lung and breast cancer diagnostics are at the forefront, driven by high incidence rates and advancements in personalized treatments, indicating robust growth potential. Colorectal and prostate cancer segments are also significant, benefiting from early detection technologies and growing awareness. Liver cancer diagnostics, though smaller, are gaining traction with innovations in imaging and biomarkers. The "Others" category captures emerging focus areas, promising future growth through novel diagnostic methods. Collectively, these applications highlight the market's dynamic nature, with each segment contributing to the overall expansion, driven by technological advancements, increasing prevalence, and the push towards early and precise diagnostics.

Market Breakup by End User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Research Institutes
  • Others

The global cancer diagnostics market, categorized by end users into hospitals and clinics, diagnostic centers, research institutes, and others, illustrates a diverse landscape of growth drivers. Hospitals and clinics, as primary care centers, are central to the market's expansion, benefiting from comprehensive diagnostic and treatment capabilities. Diagnostic centers, specialized in advanced cancer detection technologies, are pivotal for early diagnosis, positioning them for substantial growth. Research institutes play a crucial role in the development of innovative diagnostic tools and methodologies, driving future market advancements. The "others" category, encompassing a range of healthcare facilities, contributes to market diversity and expansion. Together, these end-user segments are instrumental in shaping the cancer diagnostics market, each facilitating access to crucial diagnostic services and fostering growth through technological advancements and the increasing demand for early cancer detection.

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

The global cancer diagnostics market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, each contributing uniquely to the market's dynamics. North America leads, propelled by advanced healthcare infrastructure, high healthcare expenditure, and strong research initiatives. Europe follows closely, with its robust healthcare systems and significant investments in cancer research and diagnostics. The Asia Pacific region is witnessing rapid growth, driven by increasing awareness, rising cancer prevalence, and improving healthcare facilities. Latin America and the Middle East and Africa are emerging markets, showing potential due to growing healthcare investments and an expanding focus on early cancer detection. Collectively, these regions encapsulate the global reach of the cancer diagnostics market, highlighting diverse growth opportunities and challenges, with technological advancements and healthcare priorities shaping regional market expansions.

Global Cancer Diagnostics Market Competitive Landscape

The competitive landscape of the market is defined by the activities of leading companies. These key players are engaged in a variety of strategic initiatives including mergers and acquisitions, research and development efforts, product launches, and collaborations to strengthen their market positions and expand their product portfolios. Major companies in the market are as follows:

  • Thermo Fisher Scientific
  • PerkinElmer
  • Stemcell Technologies
  • Merck
  • Bio-Rad Laboratories
  • Agilent Technologies
  • Promega
  • Bio-Techne
  • Cell Biolabs

Key Questions Answered in the Report

  • What is the current and future performance of the global cancer diagnostics market?
  • What are the factors that influence the growth, decline, and potential of the market?
  • What strategies are key players in the market adopting to strengthen their market positions?
  • How do different end-user segments contribute to the growth of the global cancer diagnostics market?
  • How do various cancer types contribute to the dynamics and growth of the global cancer diagnostics market?
  • How does each technology segment contribute to the growth of the global cancer diagnostics market?
  • How do the consumables and instrument segments influence the growth of the global cancer diagnostics market?
  • How is the market organized in terms of competition?
  • What are the main players/companies in the market?

Key Benefits for Stakeholders

  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global cancer diagnostics market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global cancer diagnostics market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global cancer diagnostics industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cancer Diagnostics Market Overview
3.1 Global Cancer Diagnostics Market Historical Value (2017-2023)
3.2 Global Cancer Diagnostics Market Forecast Value (2024-2032)
4 Global Cancer Diagnostics Market Landscape*
4.1 Global Cancer Diagnostics: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cancer Diagnostics: Product Type Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Application
5 Global Cancer Diagnostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cancer Diagnostics Market Segmentation (2017-2032)
6.1 Global Cancer Diagnostics Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Consumables
6.1.3 Instruments
6.2 Global Cancer Diagnostics Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 In-Vitro Diagnostics
6.2.3 Imaging
6.2.4 Biopsy Instruments
6.2.5 Others
6.3 Global Cancer Diagnostics Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Lung Cancer
6.3.3 Breast Cancer
6.3.4 Colorectal Cancer
6.3.5 Prostate Cancer
6.3.6 Liver Cancer
6.3.7 Others
6.4 Global Cancer Diagnostics Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals & Clinics
6.4.3 Diagnostic Centers
6.4.4 Research Institutes
6.4.5 Others
6.5 Global Cancer Diagnostics Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Cancer Diagnostics Market (2017-2032)
7.1 North America Cancer Diagnostics Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Consumables
7.1.3 Instruments
7.2 North America Cancer Diagnostics Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Lung Cancer
7.2.3 Breast Cancer
7.2.4 Colorectal Cancer
7.2.5 Prostate Cancer
7.2.6 Liver Cancer
7.2.7 Others
7.3 North America Cancer Diagnostics Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Cancer Diagnostics Market (2017-2032)
8.1 Europe Cancer Diagnostics Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Consumables
8.1.3 Instruments
8.2 Europe Cancer Diagnostics Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Lung Cancer
8.2.3 Breast Cancer
8.2.4 Colorectal Cancer
8.2.5 Prostate Cancer
8.2.6 Liver Cancer
8.2.7 Others
8.3 Europe Cancer Diagnostics Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Cancer Diagnostics Market (2017-2032)
9.1 Asia Pacific Cancer Diagnostics Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Consumables
9.1.3 Instruments
9.2 Asia Pacific Cancer Diagnostics Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Lung Cancer
9.2.3 Breast Cancer
9.2.4 Colorectal Cancer
9.2.5 Prostate Cancer
9.2.6 Liver Cancer
9.2.7 Others
9.3 Asia Pacific Cancer Diagnostics Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Cancer Diagnostics Market (2017-2032)
10.1 Latin America Cancer Diagnostics Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Consumables
10.1.3 Instruments
10.2 Latin America Cancer Diagnostics Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Lung Cancer
10.2.3 Breast Cancer
10.2.4 Colorectal Cancer
10.2.5 Prostate Cancer
10.2.6 Liver Cancer
10.2.7 Others
10.3 Latin America Cancer Diagnostics Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Cancer Diagnostics Market (2017-2032)
11.1 Middle East and Africa Cancer Diagnostics Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Consumables
11.1.3 Instruments
11.2 Middle East and Africa Cancer Diagnostics Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Lung Cancer
11.2.3 Breast Cancer
11.2.4 Colorectal Cancer
11.2.5 Prostate Cancer
11.2.6 Liver Cancer
11.2.7 Others
11.3 Middle East and Africa Cancer Diagnostics Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Abbott Laboratories
17.1.1 Financial Analysis
17.1.2 Product Type Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Thermo Fisher Scientific
17.2.1 Financial Analysis
17.2.2 Product Type Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Illumina Inc.
17.3.1 Financial Analysis
17.3.2 Product Type Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4.1 Financial Analysis
17.4.2 Product Type Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Type Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Becton, Dickinson, and Company
17.6.1 Financial Analysis
17.6.2 Product Type Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Koninklijke Philips N.V.
17.7.1 Financial Analysis
17.7.2 Product Type Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Siemens Healthineers
17.8.1 Financial Analysis
17.8.2 Product Type Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Hologic Inc.
17.9.1 Financial Analysis
17.9.2 Product Type Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 GE Healthcare
17.10.1 Financial Analysis
17.10.2 Product Type Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Agilent Technologies Inc.
17.11.1 Financial Analysis
17.11.2 Product Type Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Quest Diagnostics
17.12.1 Financial Analysis
17.12.2 Product Type Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Biomerieux SA
17.13.1 Financial Analysis
17.13.2 Product Type Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Myriad Genetics
17.14.1 Financial Analysis
17.14.2 Product Type Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
List not exhaustive!
18 Global Cancer Diagnostics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Illumina Inc.
  • F. Hoffmann La Roche Ltd.
  • Becton, Dickinson, and Company
  • Koninklijke Philips N.V.
  • Siemens Healthineers
  • Hologic Inc.
  • GE Healthcare
  • Agilent Technologies Inc.
  • Quest Diagnostics
  • Biomerieux SA
  • Myriad Genetics



Table Information